US FDA: Lilly antidepressant promotion misleading
WASHINGTON, Oct 2 (Reuters) - Eli Lilly and Co (LLY.N: Quote, Profile, Research, Stock Buzz) made misleading claims about its Cymbalta antidepressant in a promotion to doctors, U.S. regulators said in a letter released on Tuesday.
The promotion "is false or misleading in that it overstates the efficacy of Cymbalta and omits some of the most serious and important risk information associated with its use," the Food and Drug Administration said in a letter to the company. (Reporting by Lisa Richwine)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Sphere
Piracy fight
Obama visits Jewish shrine